lysophosphatidic acid


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to lysophosphatidic acid: lysophosphatidylcholine

ly·so·phos·pha·tid·ic ac·id

(lī'sō-fos'fă-tid'ik as'id),
A phosphatidic acid in which only one of the two hydroxyl groups of the glycerophosphate is esterified; most commonly, when carbon-1 of the glycerol moiety is esterified (for example, 1-acylglycerol-3-phosphate).

lysophosphatidic acid

Abbreviation: LPA
C21H41O7P, an acid purified from the ascitic fluid of patients with ovarian cancer. LPA stimulates the growth of ovarian cancer and may be a useful screening test for the disease.
CAS # 22002-87-5
See also: acid
References in periodicals archive ?
LPA(4)/ GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation.
Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Expression of lysophosphatidic acid receptor 3 in the uterine endometrium of pigs with somatic cell nuclear transfer cloned conceptuses.
Analysis of lysophosphatidic acid (LPA) receptor and LPA-induced endometrial prostaglandin-endoperoxide synthase 2 expression in the porcine uterus.
Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy.
In a comparison study of lysophosphatidic acid (LPA) and cancer antigen 125 (CA-125) in a small group of patients, LPA identified 9 of 10 with stage I ovarian cancer, while CA-125 identified 2 of 9, said Dr.
Lysophosphatidic acid, which is a lipid rather than a protein, appears to be a promoter of the growth of cancer cells, Dr.
The company said that the partnership will focus on the development of bioactive lipid lysophosphatidic acid (LPA).
Edg receptors are G-protein coupled receptors that bind either 1-oleoyl lysophosphatidic acid (LPA) or sphingosine 1-phosphate (S1P).
OB) announced on Wednesday the issuance of the key US Patent No 8,158,124 to protect Lpathomab, a monoclonal antibody against lysophosphatidic acid (LPA).
The company said that the acquisition of Amira's fibrosis programme, including the lead asset AM152, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist which has completed Phase I clinical studies and is now poised for Phase IIa proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic Sclerosis (SSc), marks its entry into fibrotic diseases, an area which is reportedly complementary to its current therapeutic areas of focus.
Lpath believes that with assistance from the NIH for neuropathic pain and from various partners/collaborators for other central-nervous-system disorders and for fibrosis, it can generate compelling data that validates its unique approach to neutralising lysophosphatidic acid (LPA), with Lpathomab.